Health brief
Clinical AI Integrations and RNA Trial Breakthroughs
Israeli hospitals advance RNA cancer therapies and enterprise OpenAI partnerships while health officials manage heatwaves and West Nile cases.
Health
Sheba Medical Center became OpenAI's first hospital partner outside the US — embedding clinical AI models directly into medical workflows.
BackgroundEnterprise clinical AI deployments integrate large language models directly into secure hospital software networks to support medical documentation and diagnostic reasoning. Sheba's ARC innovation center leads digital health technology integrations across Israel's healthcare system.
- Medical staff across Sheba will deploy OpenAI enterprise models tailored to internal clinical protocols, accelerating patient documentation and reducing physician burnout.
- The platform targets administrative documentation automation and evidence-backed clinical reasoning support, allowing doctors to reference complex medical literature in real time.
- Deployments proceed despite ongoing Israeli Ministry of Health cautions regarding public generative AI in hospitals, establishing enterprise security boundaries.
Health
Ichilov Hospital is leading a trial for RNA pancreatic cancer therapy — targeting mutated KRAS genes to overcome chemo resistance.
BackgroundMutated KRAS genes act as primary drivers for aggressive pancreatic cancer growth and have historically proven difficult to target with conventional pharmaceuticals. Direct RNA delivery methods seek to silence mutated genes inside tumor cells to overcome resistance.
- The clinical trial evaluates SIL204 small interfering RNA therapy delivered alongside standard chemotherapy to disable tumor growth mechanisms directly inside pancreatic tissue.
- Led by Prof. Ravit Geva, initial trial runs will enroll 18 patients at Ichilov before expanding treatment across medical sites in Israel and Germany.
- Silexion Therapeutics engineered the biological treatment to bypass dense stroma surrounding locally advanced tumors, potentially expanding treatment options for non-operable patients.
Health
Jerusalem issued extreme heatwave advisories as temperatures approach 47°C — triggering health precautions across the country.
BackgroundExtreme summer heatwaves across the Levant present severe public health risks including heatstroke, severe dehydration, and cardiovascular strain. Israeli emergency medical services adjust operational readiness during major weather alerts to handle surge hospital admissions.
- Jordan Valley and Sea of Galilee regions expect peak temperatures reaching 47°C, while Jerusalem prepares for unusual 36°C highs.
- Health officials warned high-risk groups including the elderly, infants, and pregnant women to remain indoors in air-conditioned environments.
- Magen David Adom emergency medical services issued strict public warnings against leaving children or animals in parked vehicles during peak heat hours.
Health
Hadassah and Hebrew University are co-leading a €15M EU clinical trial — deploying phage therapy to fight antibiotic-resistant UTIs.
BackgroundBacteriophages are targeted natural viruses engineered to attack specific bacterial strains without damaging surrounding healthy human tissue. Phage therapy offers promising solutions against antibiotic-resistant superbugs that cause chronic infections unresponsive to standard drugs.
- The clinical trial will enroll 220 female patients across Israel, the US, UK, Canada, France, and Italy to establish international efficacy data.
- Personalized bacteriophage cocktails target antibiotic-resistant E. coli bacteria causing recurrent infections, providing an alternative to chronic antibiotic regimens.
- The study is led by Israeli Phage Therapy Center researchers Prof. Ronen Hazan and Prof. Ran Nir-Paz to advance precision virology into mainstream medicine.
Health
Health
Health
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.